Optimi Health ( (TSE:OPTI) ) has provided an announcement.
Optimi Health has completed its second shipment of GMP-certified MDMA capsules to Australia, significantly enhancing its production forecast to supply over 5,000 patients globally by 2025. This expansion underscores Optimi’s commitment to providing reliable access to high-quality MDMA-assisted therapies, supporting PTSD treatments and clinical trials. The partnership with Mind Medicine Australia emphasizes the growing confidence in MDMA-assisted therapy as a treatment for PTSD, ensuring practitioners have the necessary resources and training. The initiative also aims to gather extensive real-world evidence on MDMA therapy outcomes, contributing to global mental health strategies and promoting equitable access to these transformative treatments.
More about Optimi Health
Optimi Health is a Health Canada-licensed company specializing in the production of psychedelic pharmaceuticals, with a focus on natural psilocybin and MDMA. The company operates a purpose-built facility to manufacture GMP-certified MDMA capsules, which are distributed through a regulated pharmacy network in partnership with Mind Medicine Australia.
YTD Price Performance: 0%
Average Trading Volume: 66,840
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$19.88M
See more insights into OPTI stock on TipRanks’ Stock Analysis page.